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Clinical Care Recommendations for Cardiologists Treating Adults With
Myotonic Dystrophy
Elizabeth M. McNally, MD, PhD; Douglas L. Mann, MD; Yigal Pinto, MD, PhD; Deepak Bhakta, MD; Gordon Tomaselli, MD;
Saman Nazarian, MD, PhD; William J. Groh, MD, MPH; Takuhisa Tamura, MD; Denis Duboc, MD; Hideki Itoh, MD, PhD;
Leah Hellerstein, LCSW, MPH; Pradeep P. A. Mammen, MD
Abstract-—Myotonic dystrophy is an inherited systemic disorder affecting skeletal muscle and the heart. Genetic testing for
myotonic dystrophy is diagnostic and identifies those at risk for cardiac complications. The 2 major genetic forms of myotonic
dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features. The cardiac management of myotonic dystrophy
should include surveillance for arrhythmias and left ventricular dysfunction, both of which occur in progressive manner and
contribute to morbidity and mortality. To promote the development of care guidelines for myotonic dystrophy, the Myotonic
Foundation solicited the input of care experts and organized the drafting of these recommendations. As a rare disorder, large scale
clinical trial data to guide the management of myotonic dystrophy are largely lacking. The following recommendations represent
expert consensus opinion from those with experience in the management of myotonic dystrophy, in part supported by literature-
based evidence where available. ( J Am Heart Assoc. 2020;9:e014006. DOI: 10.1161/JAHA.119.014006.)
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M yotonic dystrophy (DM) arises from nucleotide repeatexpansions and is inherited in an autosomal dominant
manner. Myotonic dystrophy type 1 (DM1), estimated as high
as 1:2500, arises from a CTG expansion in the DMPK gene,
ranging from 51 to >1500 copies, and is a multisystem
disorder associated with cardiac complications.1,2 Myotonic
dystrophy type 2 (DM2) is attributable to a CCTG repeat
expansion in the CNBP gene, often to >5000 copies.1 Like
DM1, DM2 is associated with an increased risk for atrial
arrhythmias, conduction system slowing, ventricular
arrhythmias, cardiomyopathy, and heart failure. Not every
DM patient will develop these cardiac complications. How-
ever, the incidence of cardiac abnormalities remains signifi-
cant in DM, potentially affecting >50% of patients,3 and as
such, it is recommended that DM patients undergo regular
screening by a cardiologist familiar with neuromuscular
disease and specifically with DM, if available. Cardiac
conduction system disturbances can have sudden and
catastrophic presentations, and at the same time are
preventable through proper management. Therefore, cardiac
surveillance in DM can be lifesaving. This document repre-
sents expert opinion derived from cardiologists with experi-
ence treating cardiac complications in myotonic dystrophy.
Because DM is a rare disorder, literature-based evidence for
DM-specific recommendations is often lacking and in the
absence of published support, the group relied on clinical
experience. The Myotonic Foundation organized this collec-
tion of information, and this document was developed to
provide guidance to cardiologists who may not regularly
evaluate myotonic dystrophy in their practice. It should also
be emphasized that these recommendations were developed
for the patient with a known diagnosis of DM, which typically
implies the presence of accompanying neuromuscular symp-
toms like weakness and myotonia. The first presentation of
DM may be cardiac arrhythmias, which can precede the onset
of neuromuscular symptoms. Thus, in young patients with
unusual arrhythmias, the cardiologist should assess
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neuromuscular symptoms and consider DM as a possible
underlying diagnosis. The methods used for this document
development were similar to those used to formulate overall
care recommendations for myotonic dystrophy.4
Mechanisms of Dysrhythmias in DM
In DM1, cardiac dysrhythmia is the second leading cause of
death after respiratory failure.5 The precise mechanisms by
which DM1 promotes cardiac conduction system dysfunction
are not well understood. Characterized by toxic gain-of-
function RNA-mediated mis-splicing, abnormal splicing of the
SCN5A gene has been implicated in cardiac conduction
system disease.6 In addition, upregulation of NKX2.5 has also
been suggested to play a role in cardiac dysfunction in DM.7
For DM2, less is known about the specific molecular causes of
cardiac dysrhythmia and dysfunction, and although not well
documented, DM2 is thought to share some molecular
defects with DM1.
DM is identified as a neuromuscular disease with a cardiac
dysrhythmia risk requiring special management.8 For DM
patients, cardiac dysrhythmias may be symptomatic. There-
fore, patients should be instructed to report events including
palpitations, syncope, near syncope, dizziness, and lighthead-
edness. However, not all DM patients exhibit symptoms of
arrhythmias since some rhythm disturbances may not
produce clinical symptoms yet still be present. Regular
monitoring includes regular surface 12-lead ECG, signal
averaged ECG, 24- to 48-hour Holter monitors, patch
monitors, event monitors, and implantable loop recorders.
The precise frequency of using these surveillance modalities
depends on whether the surface ECG is normal or not and the
presence of symptoms and/or left ventricular dysfunction. In
the DM patient with evidence for prolonged ECG intervals
and/or left ventricle (LV) dysfunction, it may be necessary to
monitor yearly or even more frequently. In the DM patient
with a normal ECG and normal LV function, monitoring may be
pursued with less frequency. Whether wearable or implantable
devices will increase detection of cardiac dysrhythmias in DM
has not yet been well addressed, and future studies may
address this need.
Atrial Arrhythmias in DM
Atrial arrhythmias are commonly observed in DM1 and include
atrial tachycardias such as typical and atypical atrial flutter, as
well as atrial fibrillation.5,9,10 Atrial tachyarrhythmias may have
a slower than expected ventricular response owing to concomi-
tant atrioventricular nodal slowing, resulting in slower than
expected heart rates. Atrial arrhythmias may be among the
earliest presentation of DM1, preceding even the recognition of
muscle involvement.11 Typical criteria for anticoagulation
should be followed with special attention to 1) limitations of
the DM population in making frequent appointments for
monitoring therapeutic targets for vitamin K antagonists, and
2) the risk of falls and intracerebral hemorrhage in those with
advanced muscular involvement. Ablation for atrial dysrhyth-
mias can be successful with durable results.12 Ideally, ablations
should be performed by experienced clinicians, preferably with
a team also familiar with the sedation and anesthesia needs of
neuromuscular patients.
Atrioventricular Node Dysfunction in DM
Cardiac conduction system disease affecting the atrioventric-
ular node is well described as a progressive event in DM1 and
also occurs in DM2, although less well characterized. Like
atrial arrhythmias, cardiac conduction defects can occur in
the absence of left ventricular dysfunction and often progress
slowly. As such, regular 12-lead surface ECGs are recom-
mended to follow atrioventricular nodal prolongation. Pace-
maker implantation is recommended with a PR interval
>240 ms and a QRS duration >120 ms (Class IIb).13–15
Embolic Events and Stroke Risk in DM
Embolic events and stroke risk are believed to be increased in
DM and are thought to relate to an increased incidence of
atrial fibrillation and flutter. However, population-based stud-
ies are lacking. Scoring systems such as the Congestive heart
failure, Hypertension, Age, Diabetes, Stroke and Vascular
disease (also known as CHADS-Vasc) system can be applied,
acknowledging that these scoring systems are not designed
for younger patients with genetically mediated diseases.16
The decision regarding anticoagulation should consider the
increased fall risk related to underlying neuromuscular
disease and muscle weakness. Both warfarin-based and
newer oral anticoagulants can be used for anticoagulation in
DM. Additionally, DM is not specifically associated with
hypertension, and younger DM patients may be hypotensive,
potentially altering stroke risk and consequent recommenda-
tions for anticoagulation.17 In addition, autonomic dysfunction
is a feature of DM1,18 and this may further complicate blood
pressure response and management of embolic risk. Antico-
agulation can be pursued in DM, but with concomitant
neuromuscular weakness, fall risk is increased. Data are
lacking as to whether aspirin is beneficial in DM.
Ventricular Arrhythmias in DM
Ventricular arrhythmias are challenging to predict in DM
because of atrioventricular conduction system disease.19–23 A
widened or widening QRS on serial ECGs may portend
DOI: 10.1161/JAHA.119.014006 Journal of the American Heart Association 2
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increased risk. Regular monitoring is recommended to
evaluate the presence of ventricular arrhythmias, and the
determination for internal cardioverter defibrillator (ICD)
implant relies on standard guidelines.24,25 In the presence
of left ventricular dysfunction, left ventricular ejection fraction
<35%, ICDs should be considered for primary prevention of
ventricular arrhythmias. Given the propensity for atrioventric-
ular block, subcutaneous ICD systems are likely to be
suboptimal unless no evidence of conduction system disease
is noted. When possible, a dual chamber system is preferred.
Additionally, biventricular pacing should be considered in the
setting of left bundle branch or complete atrioventricular
block. The use of His selective or non-selective pacing has not
been assessed in this population and may be limited to the
diffuse nature of infra-Hisian conduction system disease. In
DM, with associated skeletal muscle disease, patients have
limited exercise tolerance and usual symptoms of exercise
intolerance and other heart failure symptoms may not be
present. Symptoms of syncope and presyncope should be
considered carefully in the presence of a widened QRS.
Invasive electrophysiological studies may be useful to risk
stratify DM patients, especially in the presence of an
abnormal surface ECG and unclear but potentially linked
symptoms.26 In this setting, an ECG with prolonged PR and/
or QRS intervals, bundle branch, or fascicular block, along
with potential arrhythmia linked symptoms, electrophysiolog-
ical studies can be used to evaluate His bundle-ventricular
prolongation and/or presence of VT/VF after extrasystoles.
However, this area remains relatively understudied, and
additional recommendations are expected in forthcoming
guidelines from the Heart Rhythm Society specific to neuro-
muscular disease.
Heart Failure With Reduced Ejection Fraction in
DM
LV dysfunction occurs in up to 40% of DM patients, reflecting
an increased propensity to develop cardiomyopathy and heart
failure in DM.27 Heart failure symptoms may be largely absent
because of neuromuscular disease limiting exercise tolerance.
Right ventricular failure can develop, but generally occurs in
the presence of untreated respiratory muscle weakness and
accompanying pulmonary hypertension (see comments below
about respiratory management).
Left ventricular size and function should be routinely
monitored through regular cardiac imaging. Cardiac imaging
should be performed in every DM patient at baseline and
every 1 to 5 years thereafter, if the initial imaging study is
normal. As LV dysfunction increases with age, regular annual
monitoring should be undertaken in the DM1 patient aged
>40 years, especially in the presence of an abnormal ECG,
including, but not limited to, PR interval >200 ms, QRS
>120 ms (including right or left bundle branch block),
presence of fascicular block, second or third degree atrioven-
tricular block, atrial fibrillation or flutter, or development of
ventricular arrhythmias or with any evidence of prolonged
QRS duration on routine surface ECG. In the presence of
change of symptoms including worsening fatigue, dyspnea or
other symptoms, it is reasonable to obtain additional cardiac
imaging studies.
Imaging the Heart in DM
Echocardiography constitutes a mainstay imaging modality for
its ease of use, even in wheelchair bound patients, and its ready
availability and safety. Strain rate imaging can be utilized to
improve detection of subtle left ventricular dysfunction. Cardiac
magnetic resonance imaging (CMR) is also a highly useful
modality that provides additional information with regard to
cardiac fibrosis when using gadolinium imaging.28,29 Strain
defects are readily detected using CMR and can be used as an
early sign of cardiac involvement. Although useful, CMR can be
challenging to complete successfully in a neuromuscular
patient with limited mobility and associated respiratory muscle
weakness. An experienced imaging team should be familiar with
mobility needs, limits on sedation and respiratory status before
and during the study. Furthermore, interpretation of CMR
images should be completed by those familiar with interpreting
cardiomyopathy findings.
Treating Cardiomyopathy in DM
In other forms of progressive LV dysfunction associated with
neuromuscular disease, early treatment has been shown to
slow progression of LV dysfunction.30–32 Guideline-directed
medical therapy should be used to treat LV dysfunction, as
blood pressure tolerates, acknowledging that hypotension
may limit uptitration of medications. Angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers and beta-
adrenergic blockers are well tolerated in DM, although the DM
patient may tolerate only low doses of these medications
attributable to hypotension. The efficacy of mineralocorticoid
receptor antagonism with agents like aldactone (spironolac-
tone) or eplerenone is not well described in DM patients, but
use of these agents is assumed to have the same benefit as in
other forms of heart failure. Of particular note, the use of
mineralocorticoid receptor antagonism agents in DM patients
may be noteworthy as there is some clinical data demon-
strating these agents are able to suppress atrial arrhythmias
in patients with cardiomyopathies.33–36 As in other uses of
these agents, patients should be monitored for hyperkalemia.
Additional agents such as angiotensin receptor neprolysin
inhibitors (known as ARNIs) may also be useful, although
relative hypotension may limit the use of this agent. Similarly,
DOI: 10.1161/JAHA.119.014006 Journal of the American Heart Association 3
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ivabradine may be less helpful in the myotonic setting, as
heart rates tend to be low because of cardiac conduction
disease. In the setting of LV dysfunction and the presence of a
QRS >140 ms, cardiac resynchronization therapy can be
considered if heart failure persists after optimizing medical
therapies for heart failure.
Additional Considerations in Managing the DM
Heart
Muscle disease and its effect on serum biomarkers of
renal function
With muscle disease, serum creatinine cannot be used to
monitor renal clearance because serum creatinine is low to
non-detectable in the setting of low muscle mass. Alterna-
tively, serum cystatin C has been shown to be of use in
neuromuscular disease.37,38 This is an important considera-
tion if renally-cleared novel oral anticoagulants are used for
stroke prophylaxis in patients with atrial dysrhythmia.
Managing skeletal muscle myotonia in DM
Mexiletine, a class IB antiarrhythmic agent, has been
promoted for the management of grip myotonia symp-
toms.39,40 The decision to use this agent should be made in
consultation between the neurologist and cardiologist to
assess risk/benefit. Notably, this agent did appear to be well
tolerated in clinical studies to assess its use for treating
muscle myotonia symptoms. However, as with all class I anti-
arrhythmic agents, proarrhythmic effects may be increased.
Fatigue and daytime sleepiness
DM patients frequently note excessive daytime sleepiness
and fatigue.41 Fatigue arises from many factors including but
not limited to ill-defined central nervous system aspects of
DM, sleep disordered breathing, and restless leg syndrome in
DM2.42 Sleep disorders are common in DM, and extend
beyond neuromuscular respiratory disease. Stimulants like
modafinil are used to treat excessive fatigue with benefit.43
The use of stimulants, in principle, may increase the risk for
cardiac arrhythmias and cardiac complications. However, risk
and benefit must be considered in making the decision for the
management of the DM patient’s fatigue.44 A shared decision-
making model should be used, involving the patient and
providers as some degree of risk is usually well accepted by
DM patients for the symptomatic benefit that stimulants
provide.44 It may be reasonable to increase frequency of
monitoring for arrhythmias in the myotonic patient treated
with stimulants.
Neuromuscular respiratory disease
With respiratory muscle weakness, hypoventilation with
corresponding hypercapnia and hypoxia is a common feature
in DM and is a predictor of mortality in DM.5 Management of
the DM patient requires close collaboration with experts in
managing neuromuscular respiratory weakness. Non-invasive
nocturnal ventilatory support can and should be applied to
improved daytime fatigue. Episodes of irregular heart
rhythms may be more frequent with inadequate nocturnal
support.45
Hyperlipidemia, metabolic syndrome, and exercise in
DM
As with many neuromuscular disorders, DM patients have
limited exercise capacity and may become obese and exhibit
metabolic syndrome findings. In DM1,mis-splicing of the insulin
receptor is thought to contribute to an increased presence of
diabetes mellitus.46,47 Metabolic syndrome and hyperlipidemia
have been described in DM.48,49 Diabetes mellitus and
hyperlipidemia should be treated for target goals. Statins can
be used in neuromuscular patients, and it may be helpful to
monitor the serum creatine kinase before initiating these
medications. Exercise has been suggested to be beneficial in
DM patients, but larger studies are needed.50,51 However, not
all DM patients are capable of exercising. In one report, acute
onset exercise was associated with an increase arrhythmia
propensity.52 Adequate warm up and cool down periods before
and after exercisemay help DM patients participate in exercise.
The increased risk for diabetes mellitus and metabolic
syndrome, coupled with a reduced ability to exercise, may limit
the capacity to detect significant coronary artery disease
because exertional symptoms may be minimal. Pharmacologic
stress evaluation or coronary artery angiography can be used to
detect flow limiting stenosis. The management of flow-limiting
epicardial coronary artery disease does not differ for the DM
patient and conventional guidelines should be followed. Renal
impairment may be present in DM, and if serum creatinine is
markedly diminished because of low muscle mass, serum
cystatin C can be monitored.53
Advanced management/end-of-life management
The leading cause of death in DM is neuromuscular-
associated respiratory weakness and hypoventilation, fol-
lowed by cardiac complications.54 However, there are many
exceptions, and some patients may exhibit more significant
cardiac complications in the absence of severe neuromuscu-
lar involvement. When contemplating advanced management
options like cardiac transplantation or ventricular assist
support, the degree of neuromuscular involvement, especially
respiratory function, must be weighed in decisions regarding
advanced options.55 Improved non-invasive ventilation
options have prolonged survival in neuromuscular disease.
However, even with this success, progressive muscle weak-
ness and impaired quality of life should promote dialog among
patients, caregivers and healthcare providers regarding end-
DOI: 10.1161/JAHA.119.014006 Journal of the American Heart Association 4
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of-life options. In this setting, device deactivation for ICDs
should be discussed.
Summary Recommendations
1. Baseline 12-lead ECG should be performed in all patients
upon confirmation of DM diagnosis and annually there-
after if asymptomatic.
2. Cardiac imaging should be performed in every DM
patient at baseline and every 1 to 5 years thereafter if
the initial imaging study is normal. If the baseline study
is abnormal, then imaging can be done more frequently
and should accompany a change in status like increasing
shortness of breath, or to monitor medical and/or
arrhythmia management. The preferred imaging modal-
ities include echocardiography with strain rate imaging
and CMR. Echocardiogram and CMR are both acceptable
options for screening patients. Choosing which modality
to use should be based on local expertise and acces-
sibility. The risk of a cardiomyopathy being present in
DM1 is enhanced in 1 of the following observations:
a. Abnormal ECG including (but not limited to) PR
interval >200 ms, QRS >120 ms (including right or
left bundle branch block), presence of fascicular
block, second or third degree atrioventricular
block, atrial fibrillation or flutter, or development
of ventricular arrhythmias.
b. Symptoms suggestive of heart failure (ie, dyspnea,
edema) or arrhythmias (palpitations, syncope).
c. Consideration may be given to performing more
frequent cardiac imaging in the absence of the above
findings in thosewith a combination of the following:
significantly increased CTG repeat length in DM1 (ie,
in excess of 500–1000 repeats), and age >40 years.
3. Ambulatory monitoring may be used to detect ambient
or asymptomatic arrhythmias including advanced (noc-
turnal) atrioventricular block and non-sustained ventric-
ular arrhythmias. Such monitoring should be considered
in patients with the aforementioned baseline ECG
abnormalities or in those with symptoms suggestive of
arrhythmias (see point 5 below).
4. Because of the possibility of sudden death in DM,
invasive electrophysiology testing should be considered
if non-invasive testing indicates elevated risk for serious
conduction block or arrhythmias. Electrophysiological
testing should be directed at evaluation for distal
conduction impairment (His-Purkinje disease) and
inducibility for ventricular arrhythmias, particularly
bundle branch reentrant ventricular tachycardia.
5. Syncope, presyncope, dizziness, or lightheadedness
should be considered as potential cardiogenic symptoms
in patients with DM and prompt an evaluation for tachy-
or brady-, arrhythmias and cardiomyopathy.
6. Patients and family members should be educated that
symptoms such as palpitations, syncope, or near-
syncope require prompt attention.
7. Pharmacologic treatment can be used cautiously to
control atrial fibrillation in DM. Mexiletine, a class 1B
anti-arrhythmic with pro-arrhythmic effects, is used to
treat myotonia and may provide modest relief from atrial
fibrillation. However, the use of any anti-arrhythmic
medications/treatments in DM1 requires prior evalua-
tion of the heart for underlying structural or functional
abnormalities like left ventricular dysfunction that may
complicate its use. Additionally, monitoring during drug
initiation is warranted. At a minimum, anti-arrhythmic
agents should be used with caution in particular in any
patient with conduction system disease and cardiomy-
opathy in the absence of a pacemaker or ICD. Specific
guidelines for managing atrial fibrillation do not exist for
DM, so the American Heart Association/American
College of Cardiology/Heart Rhythm Society guidelines
can be used.56 Advanced management options, including
ablation, Maze procedure, and left atrial appendage
occlusion, can be considered to reduce atrial fibrillation
and reduce thromboembolic risk.
8. Anti-myotonic medications, stimulants, and general anes-
thetics should be used with caution, as these agents can
elevate the risk of cardiorespiratory complications and
malignant hyperthermia. Patients should be evaluated
preoperatively and cared for by anesthesiologists familiar
with DM1. See https://www.myotonic.org/mdf-release
s-updated-anesthesia-guidelines
9. Management of hypotension is required only if it
becomes symptomatic.
10. DM patients with a reduced ejection fraction (EF <40%)
should be managed using the updated American College
of Cardiology/American Heart Association/Heart Fail-
ure Society of America or European Society of Cardiol-
ogy guidelines. It is reasonable to treat DM patients with
left ventricular ejection fraction <50% similarly, given the
known progression of cardiomyopathy in DM. Guidelines
for the treatment of heart failure with reduced ejection
fraction serve as a general approach for managing these
patients. Recognizing that DM patients are prone to the
development of hypotension and hyperkalemia, it may
be necessary to individualize the management of
symptomatic heart failure in DM patients.
11. Beta-adrenergic blockers, angiotensin-converting enzyme
inhibitors, or ARBs may be considered in DM patients with
LV structural/function abnormalities including left atrial
dilatation, left ventricular dilatation, mild LV dysfunction
(EF 40%–50%), and regional wall motion abnormalities not
DOI: 10.1161/JAHA.119.014006 Journal of the American Heart Association 5
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attributable to non-DM conditions (ie, coronary artery
disease, hypertensive heart disease).
12. A primary or secondary prevention pacemaker or ICD is
reasonable based on the ACC/American Heart Associ-
ation/Heart Rhythm Society “Guidelines for Device-
Based Therapy of Cardiac Rhythm Abnormalities.” A
primary prevention pacemaker or ICD in a DM patient
found to be at high risk of cardiac arrest or sudden
cardiac death from abnormalities detected via non-
invasive or invasive cardiac testing may be considered
without a guideline. Patient and family preference with
careful informed consent and the assessment of other
risk factors affecting morbidity and mortality should be
considered in the decision to implant a pacemaker or
ICD.
13. Cardiac resynchronization therapy may be offered to DM
patients with left ventricular ejection fraction ≤0.35,
NYHA functional class III (or ambulatory class IV)
symptoms, normal sinus rhythm, and intraventricular
conduction delay (QRS duration >150 ms with left
bundle branch block pattern) while on optimal guide-
line-directed medical therapy.
14. Coronary artery disease can develop in DM patients, and
exercise stress testing may not be possible with
concomitant neuromuscular involvement. Statins can
be used in DM.
15. Multidisciplinary management is needed for DM patients
including neurology, pulmonology, and anesthesiology
physicians with expertise in DM when considering
cardiovascular therapeutics, particularly invasive proce-
dures that require sedation/anesthesia.
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